Lv2
150 积分 2024-04-10 加入
Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA -mutant breast cancer
13天前
已完结
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies
1个月前
已完结
皖公网安备34019202002308
